John-Paul Dowson

Director, Reimbursement Strategy

PDCI MARKET ACCESS


All Sessions by John-Paul Dowson

Printer Friendly See Full Agenda

Agenda: Day 1 Oct 5, 2020

2:30 pm

2:30 pm

INDUSTRY EXPERT

HOW CAN WE IMPROVE CANADA’S RELATIVE ATTRACTIVENESS FOR NEW PRODUCT LAUNCHES?

Canada ranks 10th out of 14 countries on its attractiveness for new medicine launch according to PDCI’s 2022 Biopharmaceutical Ecosystem Index. To ensure Canadian patients gain access to the new medicines of the future, we must keep pace with how constantly evolving local and international market access landscapes will affect Canada’s relative attractiveness for launch in the years to come. Develop your advocacy plan by:

  • Learning how Canada currently stacks up on its Development & Commercialization Infrastructure, Regulatory Landscape, and Market Access Environment
  • Identifying the policy areas that could most effectively improve our relative attractiveness
  • Discussing what Canada’s attractiveness rankings mean to Canadian patients

Share perspectives with your senior management that can help make a difference in future new drug launches

Agenda: Day 2 Oct 6, 2020